Acute Gastrointestinal Graft-versus-Host Disease in Pediatric Patients: Serum Albumin on Day 5 from Initiation of Therapy Correlates with Nonrelapse Mortality.

Slides:

Advertisements

Similar presentations

Stephanie J. Lee, Loretta A. Williams

Advertisements

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell.

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease Melanie N. Stauber,

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation Imran Ahmad,

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation Albert C.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Stephanie J. Lee, Loretta A. Williams

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Role of the Mycobiome in Human Acute Graft-versus-Host Disease

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H Alessandro Busca, Franco Locatelli, Elisabetta.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Preengraftment Serum C-Reactive Protein (CRP) Value May Predict Acute Graft-versus- Host Disease and Nonrelapse Mortality after Allogeneic Hematopoietic.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Biology of Blood and Marrow Transplantation

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Blood and Marrow Transplant Handbook

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Extracorporeal Photopheresis versus Anticytokine Therapy as a Second-Line Treatment for Steroid-Refractory Acute GVHD: A Multicenter Comparative Analysis

Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft- versus-Host Disease and Response to Steroid Treatment Sascha Dietrich,

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

Acute Gastrointestinal Graft-versus-Host Disease in Pediatric Patients: Serum Albumin on Day 5 from Initiation of Therapy Correlates with Nonrelapse Mortality and Overall Survival Evgenios Goussetis, Anna Paisiou, Vasiliki Kitra, Ioulia Peristeri, George Vessalas, Kaliopi Stefanaki, Ioanna Panayotou, Konstantina Giamaiou, Eleftheria Kontou, Margaret Kitzoni, Maria N. Dimopoulou, Savvas Karkelis, Yota Kafritsa, Eleni Rapsomaniki, Ioannis Papassotiriou, Panagiotis Tsirigotis, Eleftheria Roma, Stelios Graphakos Biology of Blood and Marrow Transplantation Volume 17, Issue 7, Pages 1058-1066 (July 2011) DOI: 10.1016/j.bbmt.2010.11.005 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of aGVHD grade II-IV. Biology of Blood and Marrow Transplantation 2011 17, 1058-1066DOI: (10.1016/j.bbmt.2010.11.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidence of GI-aGVHD. Biology of Blood and Marrow Transplantation 2011 17, 1058-1066DOI: (10.1016/j.bbmt.2010.11.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Receiver-operator characteristics analysis. The association of serum albumin levels (day +5) with response to steroids in patients with GI-aGVHD. Biology of Blood and Marrow Transplantation 2011 17, 1058-1066DOI: (10.1016/j.bbmt.2010.11.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Patients with GI-aGVHD: the impact of serum albumin level (day +5 after onset of treatment) on NRM. Biology of Blood and Marrow Transplantation 2011 17, 1058-1066DOI: (10.1016/j.bbmt.2010.11.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Patients with GI-aGVHD: the impact of serum albumin level (day +5 after onset of treatment) on OS. Biology of Blood and Marrow Transplantation 2011 17, 1058-1066DOI: (10.1016/j.bbmt.2010.11.005) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions